Logo

Allergan's Durysta (bimatoprost implant) Receives the US FDA's Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT

Share this

Allergan's Durysta (bimatoprost implant) Receives the US FDA's Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT

Shots:

  • The approval is based on two P-III ARTEMIS studies (including 8mos. extended follow up) assessing Durysta (10mcg) vs topical timolol drops (bid) in 1-122 patients with OAG & OHT.
  • The two P-III ARTEMIS studies resulted in a 30% reduction in IOP from baseline in 12wks. primary efficacy period- meeting the predefined criteria for non-inferiority
  •  The approval expands the availability of Allergan’s EyeCue- a reimbursement service for eye care professionals facilitating the patient benefit verification & PA assistance for Allergan Eye Care products. Durysta is a prostaglandin analog- being evaluated in 5 P-III studies that support its FDA label enhancement & ROW approvals

Click here ­to­ read full press release/ article | Ref: Allergan | Image: Allergan


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions